Malignant Melanoma
240
22
29
138
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
69 trials with published results (29%)
Research Maturity
138 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.8%
38 terminated out of 240 trials
78.4%
-8.1% vs benchmark
7%
17 trials in Phase 3/4
50%
69 of 138 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 138 completed trials
Clinical Trials (240)
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Phase Ib of L-NMMA and Pembrolizumab
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors